Who are ABT-335 and rosuvastatin calcium's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abt-335-and-rosuvastatin-calcium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ABT-335 and rosuvastatin calcium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ABT-335 and rosuvastatin calcium (ABT-335 and rosuvastatin calcium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate and statin combination. Area: Cardiovascular.

phase 3 Fibrate and statin combination PPARα (ABT-335) and HMG-CoA reductase (rosuvastatin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ABT-335 and rosuvastatin calcium (ABT-335 and rosuvastatin calcium) — AstraZeneca. ABT-335 (fenofibrate) reduces triglycerides and raises HDL cholesterol by activating peroxisome proliferator-activated receptor alpha (PPARα), while rosuvastatin calcium lowers LDL cholesterol by inhibiting HMG-CoA reductase.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABT-335 and rosuvastatin calcium TARGET	ABT-335 and rosuvastatin calcium	AstraZeneca	phase 3	Fibrate and statin combination	PPARα (ABT-335) and HMG-CoA reductase (rosuvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate and statin combination class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABT-335 and rosuvastatin calcium — Competitive Intelligence Brief. https://druglandscape.com/ci/abt-335-and-rosuvastatin-calcium. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab